Saturday 17 October 2026
Export LBRX’s income statement to Excel — free account
LB Pharmaceuticals Inc
LBRX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 87.4% and free cash flow fell 579.0%, each against the same quarter a year earlier.
36.74
0.05
+0.14%
Follow LBRX
| Dec '25 | Dec '24 | |
|---|---|---|
Current Ratio |
41.44 | 3.56 |
Net Debt/EBITDA |
9.90 | 0.43 |
Debt/Assets |
0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 |
Asset Turnover |
0.00 | — |
Operating CF/Net income |
1.40 | 0.84 |
Capex/Depreciation |
(0.09) | (13.49) |
| (24.38%) | 0.00% | |
| (14.55%) | 0.00% | |
ROIC |
(311.67%) | 0.00% |
Return on Tangible Assets |
(8.33%) | (278.85%) |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% |
Free Cash Flow per Share |
(4.38) | (150.34) |
Cash per Share |
36.70 | 78.21 |
Shareholders Equity per Share |
37.45 | 55.04 |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
37.45 | 55.04 |
Free Cash Flow |
(35.26) | (53.82) |
Working Capital |
300.99 | 20.77 |
Capital Expenditures |
(0.05) | (0.77) |
Net Current Asset Value |
296.81 | 15.05 |
| Other line items | ||
Quick Ratio |
39.67 | 3.45 |
Depreciation/Fixed assets |
0.37 | 0.03 |
Cash ROIC |
(5.91%) | (112.82%) |
Accounts Payable Turnover |
0.00 | — |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(4.38) | (148.19) |
Capex per Share |
(0.01) | (2.15) |
Average Payables |
2.22 | — |
Average Assets |
173.23 | — |
Average Common Equity |
103.38 | — |
Capex to Sales |
0.00 | 0.00 |
Columns are period end dates